Long-term safety of CM512 for atopic dermatitis
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study is for people who have already completed a previous study of CM512 for atopic dermatitis. It will check if the medicine is safe and works well over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been in the earlier CM512-101102 or CM512-100001 studies for atopic dermatitis.
- You must have finished the week 18 check-up in the first study, or the final visit in the second study.
- You need to wait long enough after any other treatments before joining.
- The study doctor will also check if this study is right for you based on your health.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental tablet (LT-002-158) for adults with moderate-to-severe eczema that hasn't improved enough with standard creams. The goal is to see if the tablet is safe and helps control symptoms.
This trial tests an experimental drug called SIM0278 for people with moderate to severe atopic dermatitis (eczema). It aims to see if the drug can reduce skin symptoms and is safe to use.
This trial tests a new treatment called CM512 for people with moderate-to-severe eczema (atopic dermatitis). It aims to see if the drug can improve skin symptoms like itching and rash.
This study tests a new medicine called CMS-D001 for adults with moderate to severe eczema (atopic dermatitis) that hasn't improved enough with standard creams. Participants will receive either CMS-D001 or a placebo to see if it helps reduce itching and skin symptoms.
This is a follow-up study for people who already participated in an earlier CM512 trial for chronic rhinosinusitis with nasal polyps—a condition where growths develop inside the nose and sinuses. The study tests whether CM512 continues to help reduce these polyps.
This study follows adults with moderate to severe eczema who are eligible for or already taking systemic (pill or injection) medicines. It does not test any new drug—it simply tracks how eczema is managed in real life, which may help improve future care.
Hear when a new Atopic Dermatitis (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.